Hormone therapy and coronary heart disease risk by vasomotor menopausal symptoms

Gast, Gerrie-Cor M., Pop, Victor J.M., Samsioe, Göran N., Grobbee, Diederick E., Nilsson, Peter M., Keyzer, Jules J., Wijnands-van Gent, Colette J.M. and van der Schouw, Yvonne T. (2011) Hormone therapy and coronary heart disease risk by vasomotor menopausal symptoms. Maturitas, 70 4: 373-378. doi:10.1016/j.maturitas.2011.09.005

Author Gast, Gerrie-Cor M.
Pop, Victor J.M.
Samsioe, Göran N.
Grobbee, Diederick E.
Nilsson, Peter M.
Keyzer, Jules J.
Wijnands-van Gent, Colette J.M.
van der Schouw, Yvonne T.
Title Hormone therapy and coronary heart disease risk by vasomotor menopausal symptoms
Journal name Maturitas   Check publisher's open access policy
ISSN 0378-5122
Publication date 2011-12
Sub-type Article (original research)
DOI 10.1016/j.maturitas.2011.09.005
Volume 70
Issue 4
Start page 373
End page 378
Total pages 5
Place of publication Shannon, Ireland
Publisher Elsevier
Collection year 2012
Language eng
Formatted abstract
We examined whether the association between hormone therapy (HT) use and coronary heart disease (CHD) risk differed between women with and without vasomotor symptoms (VMS).

Study design:
We used data from a Dutch (EPOS) and Swedish (WHILA) population-based sample of 8865 women, aged 46–64 years, and free of CHD, stroke, venous thrombosis/pulmonary embolism or cancer at baseline. Data on HT use, VMS and potential confounders were collected by questionnaires.

Main outcome measures:
CHD endpoints, obtained via registries.


252 CHD cases occurred during 10.3 years of follow-up. Neither for women with nor for women without flushing or (night) sweats ever HT use was associated with CHD risk, compared with never HT use. Among women with intense VMS, ever HT use borderline significantly decreased CHD risk compared with never HT use (HR 0.48 [95% CI 0.20–1.03]). Among women without intense VMS, ever HT use was associated with a borderline significant increased CHD risk (HR 1.28 [95% CI 0.96–1.70]; P for interaction
= 0.02). However, after multivariate adjustment, as compared to never HT use, ever HT use was not associated with risk of CHD among women with or without intense VMS.

In both groups of women with and without VMS, HT use does not seem to be associated with the risk of CHD. Hence, our findings do not support the view that HT use increases the CHD risk among women with an indication, i.e. VMS, but this needs to be confirmed in specifically designed studies.
Keyword Coronary heart disease
Hormone therapy
Vasomotor menopausal symptoms
Q-Index Code C1
Q-Index Status Confirmed Code
Institutional Status Non-UQ

Document type: Journal Article
Sub-type: Article (original research)
Collections: Non HERDC
School of Public Health Publications
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 3 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 3 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Thu, 12 Jan 2012, 13:15:09 EST by Gerrie-Cor Herber-Gast on behalf of School of Public Health